We have recently shown that MV140, a sublingual PBP formulated with a different composition of whole‐inactivated bacteria to treat recurrent urinary tract infections, also generates Th1, Th17 and IL‐10 immune responses 50. The gene discussed is IL10; the disease is urinary tract infection.